To the full analysis
AbCellera Biologics stock: growth
ABCLAbCellera Biologics reported $75.13M in revenue for fiscal 2025, up 160.6% on the prior year, down 20.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
35.8%
per year from 2018 to 2025, per share 23.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | −20.3% | 35.8% |
| Revenue per share | −22.3% | 23.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $8.83M | $309K | −$1.74M |
| 2019 | $11.61M | −$2.21M | −$1.3M |
| 2020 | $233.16M | $118.92M | $8.02M |
| 2021 | $375.2M | $153.46M | $186.13M |
| 2022 | $485.42M | $158.52M | $204.7M |
| 2023 | $38.03M | −$146.4M | −$121.38M |
| 2024 | $28.83M | −$162.86M | −$186.95M |
| 2025 | $75.13M | −$146.41M | −$174.07M |
Revenue by segment
How AbCellera Biologics Inc. makes its money and how that has shifted. Names are as the company reports them.
- License62%
- Research Fees36%
- Milestone Payments1%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| License | $969K | $1.05M | $46.92M | 62.5% |
| Research Fees | $35.56M | $26.28M | $27.21M | 36.2% |
| Milestone Payments | $1.5M | $1.5M | $1M | 1.3% |
| Total revenue | $38.03M | $28.83M | $75.13M | 100% |
Revenue by region
Where AbCellera Biologics Inc. generates its revenue.
- Canada85%
- United States15%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Canada | $353.4M | $484.2M | $36M | $26.2M | $64M | 85.2% |
| United States | $21.8M | $1.2M | $2M | $2.7M | $11.1M | 14.8% |
| Total revenue | $375.2M | $485.42M | $38.03M | $28.83M | $75.13M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.